Skip to main content
Erschienen in: Annals of Surgical Oncology 11/2017

11.07.2017 | Gastrointestinal Oncology

Survival Rates for Patients with Resected Gastric Adenocarcinoma Finally have Increased in the United States

verfasst von: Elliot G. Arsoniadis, MD, Schelomo Marmor, PhD, MPH, Gustave K. Diep, BS, Jane Yuet Ching Hui, MD, MS, Eric H. Jensen, MD, Todd M. Tuttle, MD, MS

Erschienen in: Annals of Surgical Oncology | Ausgabe 11/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

In the United States, the overall survival rates for gastric adenocarcinoma have remained low, with surgical resection as the only therapy for many patients. Given the advances in multimodality treatment and the development of guidelines recommending adequate lymph node evaluation, the authors determined whether overall survival rates for patients with gastric adenocarcinoma have increased in the United States.

Methods

The study used the Surveillance Epidemiology and End Results (SEER) database to examine overall survival for patients with the diagnosis of gastric adenocarcinoma between 1988 and 2013. The study cohort was divided into five periods: 1988–1992, 1993–1997, 1998–2002, 2003–2007, and 2008–2013. Kaplan–Meier methods and Cox proportional hazards modeling were used to determine the effect that year of diagnosis had on overall survival.

Results

The diagnosis was determined for 13,470 patients between 1988 and 2013. The use of radiation therapy and the proportion of patients who had at least 15 lymph nodes evaluated significantly increased during the study period. Unadjusted Kaplan–Meier estimates demonstrated significantly better survival rates for the patients with a diagnosis of gastric cancer in the later periods (2003–2007 and 2008–2013) than for those in the three earlier periods. In our Cox proportional hazards model, recent period was associated with a significantly lower hazard of 5-year mortality.

Conclusion

This analysis demonstrated for the first time that gastric cancer survival rates have significantly improved in the United States during the past 2 decades. This observation likely reflects improved adherence to cancer treatment guidelines, including adequate lymph node evaluation and delivery of adjuvant treatment more consistently.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, et al. The global burden of cancer 2013. JAMA Oncol 2015;1:505–27.CrossRef Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, et al. The global burden of cancer 2013. JAMA Oncol 2015;1:505–27.CrossRef
3.
Zurück zum Zitat Macdonald JS, Schnall SF. Adjuvant treatment of gastric cancer. World J Surg 1995;19:221–5.CrossRefPubMed Macdonald JS, Schnall SF. Adjuvant treatment of gastric cancer. World J Surg 1995;19:221–5.CrossRefPubMed
4.
Zurück zum Zitat Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11–20.CrossRefPubMed Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11–20.CrossRefPubMed
5.
Zurück zum Zitat Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012;30:2327–33.CrossRefPubMedPubMedCentral Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012;30:2327–33.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725–30.CrossRefPubMed Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725–30.CrossRefPubMed
8.
Zurück zum Zitat Japanese Gastric Cancer Association, Japanese classification of gastric carcinoma. 2nd English ed. Gastric Cancer 1998;1:10–24CrossRefPubMed Japanese Gastric Cancer Association, Japanese classification of gastric carcinoma. 2nd English ed. Gastric Cancer 1998;1:10–24CrossRefPubMed
9.
Zurück zum Zitat Dassen AE, Lemmens VE, van de Poll-Franse LV, Creemers GJ, Brenninkmeijer SJ, Lips DJ, et al. Trends in incidence, treatment, and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands. Eur J Cancer 2010;46:1101–10.CrossRefPubMed Dassen AE, Lemmens VE, van de Poll-Franse LV, Creemers GJ, Brenninkmeijer SJ, Lips DJ, et al. Trends in incidence, treatment, and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands. Eur J Cancer 2010;46:1101–10.CrossRefPubMed
10.
Zurück zum Zitat Ebinger SM, Warschkow R, Tarantino I, Schmied BM, Guller U, Schiesser M. Modest overall survival improvements from 1998 to 2009 in metastatic gastric cancer patients: a population-based SEER analysis. Gastric Cancer. 2016;19:723–34.CrossRefPubMed Ebinger SM, Warschkow R, Tarantino I, Schmied BM, Guller U, Schiesser M. Modest overall survival improvements from 1998 to 2009 in metastatic gastric cancer patients: a population-based SEER analysis. Gastric Cancer. 2016;19:723–34.CrossRefPubMed
11.
Zurück zum Zitat Wang W, Zheng C, Fang C, Li P, Xie J, Lin J, et al. Time trends of clinicopathologic features and surgical treatment for gastric cancer: results from 2 high-volume institutions in southern China. Surgery 2015;158:1590–7.CrossRefPubMed Wang W, Zheng C, Fang C, Li P, Xie J, Lin J, et al. Time trends of clinicopathologic features and surgical treatment for gastric cancer: results from 2 high-volume institutions in southern China. Surgery 2015;158:1590–7.CrossRefPubMed
12.
Zurück zum Zitat Hundahl SA, Menck HR, Mansour EG, Winchester DP. The National Cancer Data Base report on gastric carcinoma. Cancer 1997;80:2333–41.CrossRefPubMed Hundahl SA, Menck HR, Mansour EG, Winchester DP. The National Cancer Data Base report on gastric carcinoma. Cancer 1997;80:2333–41.CrossRefPubMed
13.
Zurück zum Zitat Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010;11:439–49.CrossRefPubMed Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010;11:439–49.CrossRefPubMed
14.
Zurück zum Zitat American Joint Committee on Cancer Staging Manual. 5th ed. J. B. Lippincott: Philadelphia; 1997 American Joint Committee on Cancer Staging Manual. 5th ed. J. B. Lippincott: Philadelphia; 1997
15.
Zurück zum Zitat Smith DD, Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US population database. J Clin Oncol 2005;23:7114–24.CrossRefPubMed Smith DD, Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US population database. J Clin Oncol 2005;23:7114–24.CrossRefPubMed
16.
Zurück zum Zitat Papenfuss WA, Kukar M, Oxenberg J, Attwood K, Nurkin S, Malhotra U, et al. Morbidity and mortality associated with gastrectomy for gastric cancer. Ann Surg Oncol 2014;21:3008–14.CrossRefPubMed Papenfuss WA, Kukar M, Oxenberg J, Attwood K, Nurkin S, Malhotra U, et al. Morbidity and mortality associated with gastrectomy for gastric cancer. Ann Surg Oncol 2014;21:3008–14.CrossRefPubMed
17.
Zurück zum Zitat Bartlett EK, Roses RE, Kelz RR, Drebin JA, Fraker DL, Karakousis GC. Morbidity and mortality after total gastrectomy for gastric malignancy using the American College of Surgeons National Surgical Quality Improvement Program database. Surgery 2014;156:298–304.CrossRefPubMed Bartlett EK, Roses RE, Kelz RR, Drebin JA, Fraker DL, Karakousis GC. Morbidity and mortality after total gastrectomy for gastric malignancy using the American College of Surgeons National Surgical Quality Improvement Program database. Surgery 2014;156:298–304.CrossRefPubMed
18.
Zurück zum Zitat da Costa WL Jr, Coimbra FJ, Ribeiro HS, Diniz AL, de Godoy AL, de Farias IC, et al. Total gastrectomy for gastric cancer: an analysis of postoperative and long-term outcomes through time: results of 413 consecutive cases in a single cancer center. Ann Surg Oncol 2015;22:750–7.CrossRefPubMed da Costa WL Jr, Coimbra FJ, Ribeiro HS, Diniz AL, de Godoy AL, de Farias IC, et al. Total gastrectomy for gastric cancer: an analysis of postoperative and long-term outcomes through time: results of 413 consecutive cases in a single cancer center. Ann Surg Oncol 2015;22:750–7.CrossRefPubMed
Metadaten
Titel
Survival Rates for Patients with Resected Gastric Adenocarcinoma Finally have Increased in the United States
verfasst von
Elliot G. Arsoniadis, MD
Schelomo Marmor, PhD, MPH
Gustave K. Diep, BS
Jane Yuet Ching Hui, MD, MS
Eric H. Jensen, MD
Todd M. Tuttle, MD, MS
Publikationsdatum
11.07.2017
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 11/2017
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-017-5992-2

Weitere Artikel der Ausgabe 11/2017

Annals of Surgical Oncology 11/2017 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.